AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 271 min read

BTIG reiterates Buy rating on Faeth Therapeutics, $55 price target

BTIG maintained a Buy rating on Faeth Therapeutics with a $55 price target, suggesting a 226.8% upside from the last close. The firm highlighted the strong efficacy and safety of the PIKTOR program in treating endometrial and breast cancer, as well as its competitive advantage in tolerability.

Original reporting
tradingview.com
Published Oct 27, 2026, 9:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 9:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG reiterates Buy rating on Faeth Therapeutics, $55 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The higher price target could trigger short-term buying pressure, but the underlying clinical risk remains.

02

Market read

Analyst upgrade with a substantial price target increase may move the stock modestly.

03

What to watch

Potential regulatory or trial setbacks could delay commercialization.

Relevance 5/10Novelty 4/10Timing: today

Background

BTIG's analyst note reiterates a Buy rating for Faeth Therapeutics, a biotech focused on endometrial and breast cancer treatments.

Market effects

Sector

May lift sentiment in the biotech/oncology space.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

The target may be overly optimistic given early-stage data.

Key entities

  • company
    Faeth Therapeutics

    Biotech developing the oral PIKTOR program for cancer.

  • analyst
    BTIG

    Equity research firm issuing the rating.

Read at source← All news

Related articles

OCT 23
$FTHMedAI 8/10

Faeth Therapeutics: Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

Faeth Therapeutics (FTH) presented preclinical data at ESMO 2026, showing PIKTOR inhibited tumor growth in breast cancer models, comparable or better than gedatolisib. PIKTOR, in combination with fulvestrant and palbociclib, achieved complete tumor growth inhibition. The company expects topline data from FTH-PIK-201 trial in endometrial cancer by year-end 2026 and interim data from FTH-PIK-101 trial in breast cancer in 2027.

finanznachrichten.de2 min
OCT 23
$FTHMedAI 8/10

Faeth presents preclinical data on PIKTOR in breast cancer

Faeth Therapeutics (FTH) presented preclinical data at the European Society for Medical Oncology Congress 2026, showing its drug PIKTOR inhibited tumor growth in breast cancer mouse models. PIKTOR, a combination of serabelisib and sapanisertib, achieved complete tumor growth inhibition or regression when combined with fulvestrant and palbociclib. The company is conducting Phase 2 trials in endometrial and breast cancer, with data expected by year-end 2026 and 2027, respectively.

investing.com2 min
OCT 7
$FTHMedAI 8/10

Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout

Sensei Biotherapeutics (FTH) presented data supporting its PIKTOR regimen, combining serabelisib and sapanisertib, ahead of an upcoming trial readout. The company reported improved progression-free survival in endometrial cancer patients and highlighted safety and dose-selection data. It also discussed potential market opportunities in breast and endometrial cancer, estimating a $5 billion and $1.5 billion annual market, respectively.

finance.yahoo.com2 min
AUG 17
$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) shares rose 5.8% after the FDA granted Fast Track designation to PIKTOR, an investigational all-oral combo of sapanisertib and serabelisib with paclitaxel for advanced or recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterations. The article cites a $54.50 consensus 12-month target and Phase 2 PIK-201 topline data expected by year-end 2026.

investing.com3 min